Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-600-7373
Debt
Current Ratio26.20
Quick Ratio26.20
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book2.12
Profitability
Net Income$-31,520,000.00
Net MarginsN/A
Return on Assets-27.59%
Miscellaneous
Employees12
OptionableOptionable
Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences Inc (NASDAQ:NERV) announced its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.07. View Minerva Neurosciences' Earnings History.
When is Minerva Neurosciences' next earnings date?
What price target have analysts set for NERV?
0 brokers have issued 12-month price objectives for Minerva Neurosciences' stock. Their predictions range from $19.00 to $19.00. On average, they anticipate Minerva Neurosciences' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 163.5% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.
Has Minerva Neurosciences been receiving favorable news coverage?
Media coverage about NERV stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Minerva Neurosciences earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include Spectrum Pharmaceuticals (SPPI), Kiniksa Pharmaceuticals (KNSA), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), Retrophin (RTRX), Tricida (TCDA), Deciphera Pharmaceuticals (DCPH), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN) and Athenex (ATNX).
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
- Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
- Dr. Michael Davidson, Chief Medical Officer (Age 69)
- Mr. Richard Russell, Pres (Age 55)
- Mr. Joseph Reilly, Sr. VP & COO (Age 44)
How do I buy shares of Minerva Neurosciences?
Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of NERV stock can currently be purchased for approximately $7.21.
How big of a company is Minerva Neurosciences?
Minerva Neurosciences has a market capitalization of $283.76 million. The biopharmaceutical company earns $-31,520,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Minerva Neurosciences employs 12 workers across the globe.
What is Minerva Neurosciences' official website?
How can I contact Minerva Neurosciences?
Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]
MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
